Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Vaginal estriol on urogenital symptoms in Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
12-001

Urinary tract dysfunction is seen in 80% of the MS patients. Symptoms include urinary frequency, urgency, incontinence, retention and frequent urinary tract infections. Bladder dysfunction interferes with daily activities and has a major impact in the patient’s quality of life.

Oral estriol is associated with entero- hepatic recirculation which prolongs exposure due to recycling. Vaginal estrogen delivery has a regional benefit to the lower urogenital tract. This study showed a statistically significant benefit in urogenital symptoms and quality of life of MS patients treated with vaginal estriol.

To evaluate the benefit of adjunctive vaginal estriol in female patients with relapsing-remitting multiple sclerosis and urogenital dysfunction.

Vaginal estriol (1mg) was prescribe as adjunctive therapy in female patients with RRMS who wished to participate in the trial and had history of hysterectomy or menopause. Urogenital (BLCS) questionnaire was done at baseline 6 and 9 months. Quality of life questionnaire (MSQoL) was performed at baseline and 9 months. Patients with progressive MS, personal history of breast uterine or ovarian cancer were excluded. Levels of estriol, FSH, LH were done at baseline and 9 months. Pilot study included 12 patients.

Improvement of bladder disfunction symptoms were observed among all participants at 6 and 9 months. Statistically significant improvements were observed for BCLS Questionnaire (p =0.001*) as well as in quality of life questionnaire MSQoL 54 Physical (p = 0.009*), and MSQoL 54 Mental (p = 0.042*). Statistically significant improvements were observed for Urinary urgency (p = 0.008*), Urinary frequency (p = 0.002*), and Frequent UTI (p = 0.016*).

Adjunctive vaginal estriol (1mg) significantly improved bladder disfunction symptoms and quality of life in RRMS patients.

Authors/Disclosures
Mirla L. Avila, MD (Texas Tech University Health Sciences Center)
PRESENTER
Dr. Avila has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Genzyme, BMS, Serono. Dr. Avila has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen, genzyme, BMS. The institution of Dr. Avila has received research support from Texas Tech.
Roberto Hernandez Quintana, MD (Texas Tech University/UMC) Dr. Hernandez Quintana has nothing to disclose.
Jie Pan, MD Dr. Pan has nothing to disclose.
Smathorn Thakolwiboon, MD (Mayo Clinic Health System) Dr. Thakolwiboon has nothing to disclose.
Dargelis Chi, MD (Clinical Neurophysiology - University of Miami/Jackson Health System) Dr. Chi has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file